Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
15 March 2018Website:
http://www.arcusbio.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
RCUS Latest News
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 3,500 shares of the Company's common stock at an exercise price per share of $16.41, which was the closing price on June 24, 2024, and rest.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 36,100 shares of the Company's common stock at an exercise price per share of $16.09, which was the closing price on June 10, 2024, and res.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced the completion of patient enrollment for STAR-221, a Phase 3 study in collaboration with Gilead Sciences, evaluating the combination of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 monoclonal antibody zimberelimab and chemotherapy in patients.
Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 16,300 shares of the Company's common stock at an exercise price per share of $16.28, which was the closing price on May 23, 2024, and re.
Arcus Biosciences (RCUS) lacks the necessary elements for a potential earnings surprise in its upcoming report. Be ready with the key projections.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Biopharma Conference 2024 Date: Monday, March 11th, 2024 at 4:00 p.m. ET Location: Miami Beach, FL Format: Fireside Chat Barclays 26th Annual Global Healthcare Co.
The average of price targets set by Wall Street analysts indicates a potential upside of 151.6% in Arcus Biosciences, Inc. (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript
Arcus Biosciences is developing a combination therapy of PD-1 and TIGIT inhibitors for esophagogastric cancer, showing promising efficacy in a phase 2 study. The company's most advanced molecule, domvanalimab, is being investigated in lung cancer and upper GI tract cancers in collaboration with Gilead Sciences. Preliminary findings from the EDGE-Gastric study showed a positive response rate of 56% in patients receiving the dom-zim-chemo combination for upper GI cancers.
What type of business is Arcus Biosciences?
Arcus Biosciences Inc is a biopharmaceutical company operating in the clinical stage. It is developing immunotherapy for the treatment of cancer. The company focuses on the adenosine triphosphate (ATP)-adenosine pathway, which is a key factor in immunosuppression in the tumor microenvironment, to create and optimize differentiated low molecular weight candidate drugs for immuno-oncology. Its product pipeline includes Domvanalimab, Etrumadenant, AB680 and Zimberelimab. Arcus is conducting clinical trials for various types of cancer, such as prostate cancer, lung cancer, colorectal cancer, pancreatic cancer, and others. The company operates in a single segment, focusing on the development and commercialization of immunotherapeutic drugs. The company was founded in 2015 and is based in Hayward, California.
What sector is Arcus Biosciences in?
Arcus Biosciences is in the Healthcare sector
What industry is Arcus Biosciences in?
Arcus Biosciences is in the Biotechnology industry
What country is Arcus Biosciences from?
Arcus Biosciences is headquartered in United States
When did Arcus Biosciences go public?
Arcus Biosciences initial public offering (IPO) was on 15 March 2018
What is Arcus Biosciences website?
https://www.arcusbio.com
Is Arcus Biosciences in the S&P 500?
No, Arcus Biosciences is not included in the S&P 500 index
Is Arcus Biosciences in the NASDAQ 100?
No, Arcus Biosciences is not included in the NASDAQ 100 index
Is Arcus Biosciences in the Dow Jones?
No, Arcus Biosciences is not included in the Dow Jones index
When does Arcus Biosciences report earnings?
The next expected earnings date for Arcus Biosciences is 07 August 2024